Dengue Treatment: Drug Names & Brands Stocked in India
The medicines actually used in dengue management in India — paracetamol brands, ORS formulations, IV fluids and platelet support — per NVBDCP guidelines.
This covers which drug categories a hospital pharmacy actually needs to stock for dengue admissions, the commonly available Indian dengue names within each category, and why certain widely available over-the-counter analgesics have no place in a dengue treatment protocol. Patients and attendants searching dengue names online frequently land on lists mixing appropriate supportive-care products with unsuitable NSAID combinations, which is exactly the confusion a hospital pharmacy needs to screen out at the counter.
What drug categories does dengue management in India actually use?
Indian national guidelines call for four categories: antipyretics (paracetamol only), oral or IV fluids for rehydration, colloid solutions for shock in severe dengue, and blood products including platelet concentrates or fresh whole blood where indicated. NVBDCP's guidelines on clinical management of DF/DHF/DSS set out this framework, later updated in the 2023 National Guidelines for Clinical Management of Dengue Fever.
No antiviral, antibiotic or dengue-specific drug sits in this list. That is a structural fact of dengue management, not a gap in Indian protocol specifically — no country's national guideline currently includes a licensed antiviral for dengue. A hospital building its dengue stock list should plan around these four categories directly rather than searching for a dengue-specific product that doesn't exist in current clinical practice.
Which paracetamol brands are relevant to dengue fever management?
Among the dengue names most relevant to a hospital pharmacy, paracetamol brands top the list as the sole antipyretic recommended across Indian dengue guidelines — widely stocked as Crocin, Dolo, Calpol and Paracip, alongside generic formulations. Dosing is decided by the treating physician based on weight, hepatic status and platelet trend.
Hepatic caution matters specifically in dengue because the virus itself can cause transaminitis, and stacking paracetamol dosing on top of dengue-related liver stress is a decision for the treating clinician to titrate, not a fixed instruction a patient should self-administer without monitoring. A hospital pharmacy stocking for dengue season needs enough paracetamol volume, across both tablet and IV formulations, to cover a ward that can fill rapidly during a monsoon-linked case surge.
Why are NSAIDs and aspirin brands excluded from dengue treatment stock?
Aspirin, ibuprofen and other NSAIDs are contraindicated in dengue because of their antiplatelet and gastric-irritant effects, which can worsen the bleeding tendency and gastritis risk that dengue itself already produces, per both NVBDCP guidance and peer-reviewed clinical pharmacology literature. This rules out common combination analgesic brands that contain ibuprofen or aspirin as a component, not just standalone NSAID products.
A hospital pharmacy managing a dengue ward needs a stocking policy that actively screens out NSAID-containing combination products at dispensing, since many patients or attendants bring in or request a familiar analgesic brand without realising it contains an NSAID component unsuitable for a dengue diagnosis. This is precisely the kind of substitution error that an in-house, hospital-supervised pharmacy is positioned to catch and an outside retail counter, working from a walk-in request alone, often isn't.
What fluid and electrolyte products does a dengue admission require?
The dengue names list extends well beyond antipyretics into fluid therapy: oral rehydration solution, IV crystalloids such as normal saline or Ringer's lactate, and colloid solutions like Dextran 40 or haemaccel for shock, per NVBDCP clinical guidelines.
Volume management is titrated against hematocrit trend and platelet count rather than a fixed volume protocol, since over-hydration in dengue shock syndrome carries its own risk of pulmonary oedema.
ORS is available across widely stocked Indian brands including Electral and ORSL, alongside WHO-formulation generic ORS sachets distributed through government health facilities. A hospital's fluid stock needs both oral and IV options available simultaneously, since a patient's status can shift from tolerating oral intake to requiring IV support within hours during the critical phase.
What blood products does severe dengue management call for?
Platelet concentrates and fresh whole blood transfusion are indicated in severe dengue when the treating team identifies a low or falling platelet count alongside active bleeding or falling hematocrit, per national clinical guidelines. The decision itself sits with the clinical team, not a fixed lab-value trigger.
Platelet count above 50,000/mm³ or a rising trend factors into decisions on discharge readiness. Fresh whole blood transfusion becomes relevant specifically when hematocrit is falling alongside other severe dengue markers, weighing bleeding risk against the resource cost of blood product use.
Fresh whole blood transfusion at a dose set by the treating team is indicated specifically when hematocrit is falling alongside other severe dengue markers, per NVBDCP guidance. This is a hospital blood bank and transfusion medicine function, not a pharmacy stocking decision in the retail sense, but it does mean a hospital managing dengue caseload needs functioning blood bank access, either in-house or through a rapid-referral arrangement.
How should a hospital pharmacy stock for a dengue season surge?
Dengue caseload in India spikes sharply during and after monsoon months, and a pharmacy that hasn't pre-positioned paracetamol, ORS and IV fluid stock ahead of that seasonal curve ends up either running short during peak admissions or sending patients' attendants out to buy supplies from an outside chemist mid-admission. Neither outcome serves the patient or the hospital.
That second scenario is where in-house stocking reliability becomes a revenue question as much as a clinical one. Every time a dengue patient's family is sent outside the hospital gate to buy paracetamol, ORS or an IV set because the in-house pharmacy ran short, that purchase — and the continuity of the pharmacy record with it — leaves the institution. Medyzen's managed hospital pharmacy services are built around exactly this kind of seasonal-surge stocking reliability, and our piece on prescription leakage covers what that walk-out actually costs a hospital across a full dengue season. Our pharmacy inventory management guide covers the reorder discipline that keeps seasonal stock like this from running short or expiring unused between dengue seasons.
Sources
- 1National Guidelines for Clinical Management of Dengue Fever 2023 — National Centre for Vector Borne Diseases Control, MoHFW
- 2Guidelines for Clinical Management of DF/DHF/DSS — National Vector Borne Disease Control Programme
- 3Symptomatic treatment of dengue: should the NSAID contraindication be reconsidered? — PubMed, National Library of Medicine
- 4Management of Dengue Case — National Centre for Vector Borne Diseases Control
- 5Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
This article is for informational purposes and is not a substitute for professional medical advice. It lists drug categories and brand availability for hospital stocking reference; it is not a treatment protocol or a substitute for the treating clinician's assessment. Consult a qualified doctor for any suspected dengue case.
FAQ
Frequently asked questions
No. No country's national dengue guideline, including India's NVBDCP framework, currently includes a licensed antiviral drug for dengue. Management is entirely supportive — antipyretics, fluid therapy and blood product support as needed.
Paracetamol is the only antipyretic among the recommended dengue names in Indian national guidelines. Aspirin and NSAIDs including ibuprofen are specifically excluded because of their antiplatelet and gastric-irritant effects, which can worsen dengue's bleeding tendency.
Ibuprofen and other NSAIDs interfere with platelet function and increase gastric irritation risk, both of which compound the bleeding tendency dengue itself can cause, particularly as platelet counts fall during the critical phase of illness.
The decision to transfuse platelets or blood products in dengue is made by the treating clinical team based on the patient's platelet trend, bleeding status and overall clinical picture, not a single fixed number applied uniformly. National guidelines use platelet recovery above 50,000/mm³ as one factor in assessing discharge readiness.
As of current national guidelines, dengue management in India remains supportive-care based, and vaccine availability and eligibility criteria should be confirmed against current CDSCO and MoHFW guidance rather than assumed, since this is an evolving regulatory area.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.